In brief
Australia has broadened the Pharmaceutical Benefits Scheme to include a child‑friendly form of Trikafta, Tepezza for thyroid eye disease, wider access to Adcetris for Hodgkin lymphoma and adjusted dispensing limits for Repatha, aiming to benefit thousands of patients each year.
On Sunday, Canberra, the Australian government announced that effective 1 November 2026 it would expand its Pharmaceutical Benefits Scheme (PBS) to make subsidised treatment available to more patients with cystic fibrosis, blood cancer and thyroid eye disease. Health Minister Mark Butler said the changes would allow thousands of Australians to access new therapies at a fraction of their private‑market cost.
Under the new listing, children aged six to 11 who weigh less than 30 kg and have cystic fibrosis will gain eligibility for a granule form of Trikafta, a drug that targets the underlying genetic defect. The child‑friendly formulation is designed for patients who struggle to swallow tablets. The government statement estimated that about 3,300 Australians will benefit each year. Without PBS subsidies the medication could cost more than 20,300 Australian dollars (approximately 14,200 U.S. dollars) per prescription.
In addition, the PBS now includes Tepezza for active, moderate-to-severe thyroid eye disease. The drug is expected to help roughly 310 Australians annually. The inclusion follows growing evidence that Tepezza offers a safer treatment option than traditional therapies that carry a higher risk of adverse effects.
The scheme also expands subsidised access to Adcetris, a monoclonal‑antibody therapy used for CD30‑positive classical Hodgkin lymphoma. New first‑line treatment guidelines will allow more patients with advanced disease to obtain the drug, benefiting an estimated 370 Australians each year. Health Minister Butler highlighted that Adcetris is now available to patients previously limited by higher cost thresholds.
Furthermore, the PBS listing for Repatha, a medication used to treat high cholesterol, has been altered to permit the dispensing of larger quantities under the 60‑day prescription initiative. Eligible patients will pay a maximum of 25 Australian dollars per prescription, or 7.70 Australian dollars for concession card holders. The change is aimed at improving adherence for patients who require frequent refills.
The Australian government has approved 511 new and amended PBS listings since July 2022. Minister Butler noted that these reforms are part of a broader effort to improve affordability and expand access to advanced therapies for chronic and life‑threatening conditions.
Experts say the introduction of the child‑friendly Trikafta and Tepezza addresses longstanding gaps in treatment options for young patients and those with rare diseases. Dr. Eleanor Briggs, a cystic fibrosis specialist at the University of Sydney, said, “These changes represent a critical step in ensuring that children with cystic fibrosis can receive timely, life‑saving therapy without the burden of high out‑of‑pocket costs.”
However, several open questions remain in the wake of the policy shift. Analysts from the Australian Institute of Health and Welfare are monitoring how the expanded PBS listings will affect federal and state budget allocations. The Institute estimated that the additional funding could strain the PBS budget over the next decade if uptake continues to grow. Questions also arise regarding the long‑term sustainability of subsidising high‑cost drugs and whether private sector negotiations will evolve as demand expands.
Stakeholders from patient advocacy groups have raised concerns about waiting lists and potential delays in drug distribution following the scheme changes. The Australian cystic fibrosis community, for instance, will need to ensure that pharmacists and healthcare providers are equipped to handle the transition to a granule formulation. Similarly, the thyroid eye disease community will need robust monitoring protocols to detect adverse reactions to Tepezza once it enters mainstream use in Australia.
Policymakers face the challenge of balancing expanded access with fiscal responsibility. As Xinhua reported, the government has highlighted that additional funding has already been earmarked to support the new and amended PBS listings, but it has not outlined specific cost‑saving measures or timelines for reviewing the program’s financial impact. Meanwhile, the Australian National Healthcare Reform Commission has called for clearer metrics on patient outcomes to justify ongoing investment in high‑dose biologics like Adcetris and Repatha.
Critics argue that while the reforms improve access for a subset of patients, the broader population of people with chronic diseases may still confront high copayments for essential medicine. The Australian Consumer and Competition Tribunal has scheduled hearings to examine the affordability of PBS drugs introduced in the last year. The outcomes of those hearings could shape how future listings are negotiated.
Nonetheless, the PBS expansion represents a significant policy advance for Australia’s healthcare system. It aligns with global trends in encouraging equitable access to innovative medicines and responds directly to patient needs identified by clinicians and advocacy groups in the cystic fibrosis, oncology and ophthalmology communities. The long‑term success of the initiative will depend on transparent data collection, rigorous health economics evaluation, and continued dialogue between government, suppliers, clinicians and patients. As the new scheme takes effect, all eyes will be on how effectively it translates into improved health outcomes across the country.
